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Abstract
Rare coding variants in the triggering receptor expressed on myeloid cells‐2
(TREM2) gene have been associated with Alzheimer disease (AD) and homozygous
TREM2 loss‐of‐function variants have been reported in families with monogenic
frontotemporal‐like dementia with/without bone abnormalities. In a whole‐exome
sequencing study of a family with probable AD‐type dementia without pathogenic
variants in known autosomal dominant dementia disease genes and negative for
the apolipoprotein E (APOE) ε4 allele, we identified an extremely rare TREM2
coding variant, that is, a glycine‐to‐tryptophan substitution at amino acid position
145 (NM_018965.3:c.433G>T/p.[Gly145Trp]). This alteration is found in only 1 of
251,150 control alleles in gnomAD. It was present in both severely affected as well
as in another putatively affected and one 61 years old as yet unaffected family
member suggesting incomplete penetrance and/or a variable age of onset.
Gly145 maps to an intrinsically disordered region (IDR) of TREM2 between the
immunoglobulin‐like and transmembrane domain. Subsequent cellular studies
showed that the variant led to IDR shortening and structural changes of the
mutant protein resulting in an impairment of cellular responses upon receptor
activation. Our results, suggest that a p.(Gly145Trp)‐induced structural distur-
bance and functional impairment of TREM2 may contribute to the pathogenesis
of an AD‐like form of dementia.
K E YWORD S
Alzheimer disease, conformation, dementia, intrinsically disordered region, TREM2
1 | INTRODUCTION
Alzheimer disease (AD) is a multifactorial disorder characterized
by progressive and irreversible neurodegeneration, which inex-
orably leads to dementia. As with most multifactorial disorders,
susceptibility to AD results from complex interactions of genetic,
epigenetic, and environmental factors. The estimated heritability
of sporadic AD is 60–80% (Gatz et al., 2006). Since 2009, a
growing number of common and rare genetic risk variants for AD
(with minor allele frequencies [MAF] of > 5% and < 1%,
respectively), besides APOE‐ε4, have been identified by genome‐
wide association studies and next‐generation sequencing ap-
proaches. While common variants usually have small to modest
effect
sizes, the effect sizes observed for rare coding variants are
often larger and in some instances exert a similar effect as
APOE‐ε4. Several rare coding variants have been described as
susceptibility genes for AD, including alterations in TREM2, ABCA7
(ATP binding cassette subfamily A member 7), SORL1 (sortilin
related receptor 1), PLCG2 (phospholipase C gamma 2), and ABI3
(ABI family member 3). Among them, the rare coding variant
p.(Arg47His) in TREM2 confers a three‐fold increased risk for
sporadic AD (Lill et al., 2015).
TREM2 is a type I membrane protein primarily expressed by
microglial cells in the brain (Kiialainen, Hovanes, Paloneva, Kopra,
& Peltonen, 2005). The protein lacks an intracellular signaling
motif and functions by interacting with its coreceptor DAP12
(DNAX‐activating protein of 12 kDa), also known as TYROBP
(TYRO protein tyrosine kinase‐binding protein), in microglial signal
transduction (Ulland & Colonna, 2018; Villegas‐Llerena, Phillips,
Garcia‐Reitboeck, Hardy, & Pocock, 2016; Walter, 2016). Both
proteins form a plasma membrane‐localized immune receptor
complex (Wunderlich et al., 2013). TREM2 function has been
linked to ApoE and loss of TREM2 has been suggested to lead to
deficits in lipid sensing important for microglial activation and
innate immune responses (Krasemann et al., 2017; Poliani et al.,
2015; Shi & Holtzman, 2018; Yeh, Hansen, & Sheng, 2017).
Moreover, TREM2–DAP12 is also involved in the recognition of
membrane debris and amyloid deposits resulting in activation and
proliferation of microglia.
In addition to TREM2 susceptibility coding variants in AD, biallelic
variants in TREM2 have been reported in families with a rare
autosomal recessive disease called polycystic lipomembranous
osteodysplasia with sclerosing leukoencephalopathy (PLOSL, also
known as Nasu–Hakola disease; Paloneva et al., 2003). This condition
is characterized by early onset progressive dementia and bone cysts.
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In addition, biallelic TREM2 variants were also identified in families
affected by frontotemporal (FTD)‐like dementia without bone cysts
(Guerreiro et al., 2013). Of note, the majority of TREM2 variants that
are linked to aforementioned monogenic neurodegenerative dis-
eases, including p.(Arg47His), are located in exon 2 encoding the
highly conserved extracellular immunoglobulin (Ig)‐like domain. This
region contains the ligand‐binding domain of TREM2 and those rare
variants are supposed to interfere with subcellular transport and
ligand–receptor interaction, hence decreasing overall TREM2 signal-
ing activity. In most cases, however, rare variants do not reach the
level of penetrance seen in variants associated with monogenic forms
of AD (Karch & Goate, 2015). Furthermore, with the exception of
p.(Arg47His) and p.(Arg62His), a possible association of rare coding
variants in TREM2 with AD can often not be proven due to their low
MAF, rendering their classification into pathogenic and nonpatho-
genic alterations difficult (Jin et al., 2014). Therefore, the analyses of
families with clustering of dementia offers an alternative approach to
identify susceptibility variants with higher penetrance. In this study,
we summarize the identification and functional characterization
of a rare TREM2 coding variant associated with a familial form of
dementia.
2 | MATERIAL AND METHODS
2.1 | Patients and controls
A nonconsanguineous family from Portugal affected by familial
dementia was identified (Figure 1). The mother of the patient (II:2)
was diagnosed with AD at age of 76 and her grandmother on the
mother’s side (I:2) also showed late‐onset dementia. Only the index
patient (III:1) of this family could be examined in more detail.
Additional information on affected members in this family was
obtained from accompanying healthy relatives. Diagnosis of probable
AD in the index patient was assigned according to both National
Institute of Neurological and Communicative Disorders and Stroke
and the Alzheimer's Disease and Related Disorders Association
(NINCDS/ADRDA) criteria (McKhann et al., 1984) and the core
clinical of the National Institute on Aging‐Alzheimer’s Association
(NIA‐AA) criteria (McKhann et al., 2011). Consent was obtained from
all participants. The studies were approved by the respective ethics
committees. Genomic DNA was extracted from EDTA blood samples
according to standard protocols. Screening of the identified TREM2
variant was performed in Spanish and German AD cases and healthy
controls.
The Spanish sample was recruited between 2003 and 2012 at the
Memory Disorders Unit, Department of Neurology, Clínica Universi-
dad de Navarra, School of Medicine (Pamplona, Spain; Benitez et al.,
2013). Probable AD diagnoses were assigned according to both
NINCDS/ADRDA criteria (McKhann et al., 1984), and the core
clinical NIA‐AA criteria (McKhann et al., 2011). Written informed
consent was obtained from all participant of this study. The study
was approved by the local Institutional Review Board. In this
screening, 324 AD patients were included with an age at disease
onset (AAO) of 74.1 ± 5.3 (mean ± standard deviation [SD]), 40% of
patients were male. The control sample included 350 participants
without cognitive deficits with a mean age at the latest assessment of
66.5 ± 11.5, 40% of controls were male.
In the German sample, all patients fulfilled NINCDS/ADRDA
criteria for probable AD (McKhann et al., 1984). For the present
screening, 940 AD samples were analyzed with 36% males and AAO
of 72.1 ± 19.3. The patients with AD included in this study derived
from the German Dementia Competence Network (Kornhuber et al.,
2009), the German study on Aging, Cognition, and Dementia in
primary care patients (AgeCoDe; Jessen et al., 2011), and the
interdisciplinary Memory Clinic at the University Hospital of Bonn
(Ramirez et al., 2014). Detailed description on inclusion criteria and
diagnostic protocols for the AD cohort have been described
elsewhere (Heilmann et al., 2015; Ramirez et al., 2014).
Control samples were obtained from the AgeCoDe cohort.
Herein, AgeCoDe participants were included in the control group if
they remain free of any cognitive impairment until the last visit. A
total of 919 control samples were screened with 37% males and an
age at last visit of 86.9 ± 3.2.
2.2 | Whole‐exome sequencing
Whole‐exome sequencing (WES) was performed in three members of
the family after genomic DNA was isolated from EDTA blood
samples. Enrichment of exonic and adjacent intronic sequences was
performed with the NimbleGen Sequence Capture Human Exome
2.1M Array (Roche NimbleGen). Sequencing was performed on the
Illumina Genome Analyzer IIx Sequencer (Illumina). The Varbank
pipeline v2.1 and user interface, developed by the Cologne Center
for Genomics, was used for the analysis and filtering of variants
(https://varbank.ccg.uni‐koeln.de). Herein, mean coverage was at
least 68x in all three exomes (68×–81×), and ~90% of target bases
were covered more than 20×. For the variant discovery analysis, the
Genome Analysis Toolkit best practices recommendation were used
as implemented in the VarBank interface (for details on the VarBank
pipeline see [Kawalia et al., 2015] and [Alawbathani et al., 2018]).
Numbering of variants in TREM2 were done using the NCBI reference
sequence NM_018965.3.
2.3 | Chemicals
The chemicals, used in this study, were purchased from following
companies. Dulbecco’s modified Eagle's medium (DMEM),
penicillin–streptomycin (10.000 U/ml), Lipofectamine 2000, and
Opti‐MEM® for cell culture were purchased from Life Technol-
ogies. Fetal calf serum (FCS) was ordered from PAN‐Biotech,
(Germany) and Sigma‐Aldrich; phosphate‐buffered saline (PBS),
EDTA, Endo H, and PNGase F glycosidases were from NEB; poly‐
L‐lysine hydrobromide, NP‐40 (IGEPAL® CA‐630); glycerol were
purchased from Sigma‐Aldrich; and SDS pellets (sodium dodecyl
sulfate) were gained from Roth, Germany. Sodium chloride, Tris,
skimmed milk powder, glycine Tween® 20, and Triton X‐100 were
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purchased from AppliChem, Germany. Complete Mini protease
inhibitor cocktail tablets were gained from Roche Applied
Science, Germany. Bromophenol blue was used from Merck,
Germany. EZ‐Link Sulfo‐NHS‐Biotin and Pierce Streptavidin
Agarose beads were purchased from Thermo Fisher Scientific,
Germany.
2.4 | Primary and secondary antibodies
Following antibodies were used: goat anti‐hTREM2 (#AF1828, 1:1,000
diluted) from R&D Systems; mouse anti‐Flag M2 (#F1804, 1:1,000
diluted) and mouse anti‐α‐Tubulin antibody (#T5168, 1:1,000) from
Sigma‐Aldrich; mouse anti‐c‐Myc antibody (#2276, 1:1,000) from Cell
Signaling Technology, secondary antimouse and antirabbit antibodies
conjugated with horseradish peroxidase (#sc‐2030 and #sc‐2005, dilution
1:5,000) from Santa Cruz Biotechnology, Inc., secondary antibodies
conjugated with IRDye® 680LT (#926–68022 and #926–68023, dilution
1:5,000) or IRDye® 800CW (#926–32212 and #926–32213, dilution
1:5,000) were purchased from LI‐COR. Additional information of used
antibodies is given in the corresponding figure legends.
2.5 | Cell lines
Human embryonic kidney cells HEK293 were purchased from CLS
Cell Lines Service GmbH (Germany) and COS‐7 cells obtained from
DSMZ (German Collection of Microorganisms and Cell lines,
Braunschweig, Germany). The cells were maintained at 37°C in a
humidified atmosphere of 5% CO2 in air in DMEM supplemented
with 10% FCS and 1% penicillin–streptomycin (10.000 U/ml). COS‐7
cells were maintained in DMEM with GlutamaxTM.
2.6 | DNA constructs
The DNAs encoding for human proteins were cloned into
pcDNATM3.1(+) or pcDNATM3.1(−) and pEGFP‐N1 expression
vectors (#V790‐20, Life Technologies). Open reading frames of
the human TREM2 were cloned using primers attaching a DNA
sequence encoding a c‐Myc‐tag to the 5′ ends and FLAG‐tag
or GFP (green fluorescent protein) to the 3′ ends, respectively,
of the coding regions having the signal peptide in front of
the N‐terminal tag (Figure 2a). The FLAG tag was not present
in c‐Myc‐TREM2‐eGFP expression constructs (c‐Myc‐TREM2‐
eGFP). Variants NP_061838.1:p.(Gly145Trp), NP_061838.1:p.(Ar
g47His), NP_061838.1:p.(Thr66Met), NP_061838.1:p.(Gly145A
la), NP_061838.1:p.(Gly145Pro), NP_061838.1:p.(Gly145Ile), and
NP_061838.1:p.(Gly145Phe) in TREM2 encoding DNA sequence
were introduced by using QuikChange II Site‐Directed Mutagen-
esis Kit (#200523, Agilent Technologies, Germany).
2.7 | Transfection of HEK293 cells
HEK293 cells were transfected with Lipofectamine 2000 (Life
Technologies) according to manufacturer’s protocol. After 24 hr,
transfection cells were used for different experiments. Cells were
cotransfected with plasmids encoding TREM2 and its coreceptor
DAP12 to allow efficient subcellular transport of TREM2.
2.8 | Preparation of cellular membranes form
HEK293 cells
Membrane fractions from transiently transfected HEK293 cells were
prepared as described previously (Wunderlich et al., 2013). In brief,
medium was aspirated and cells were washed once with ice‐cold PBS
about 24 hr after transfection. After washing HEK293 cells were
incubated with hypotonic buffer (10 mM Tris, 1 mM EDTA, 1 mM
EGTA in dH2O, and pH 7.6) at 4°C under moderate shaking. Cell
nuclei were separated from the homogenates by centrifugation at
300 g and 4°C for 10 min. Homogenates were again centrifuged at
16,000 g and 4°C for 60 min to separate cellular membranes from
the cytosol. The pelleted membranes were lyzed by the addition of
STEN lysis buffer and incubation on ice for 15 min. Membrane
fractions were used for different biochemical analysis.
2.9 | Preparation of HEK293 cell lysates
For preparing cell lysates from transiently transfected HEK293
cells growth medium was aspirated and HEK293 cells were washed
with ice‐cold PBS (Dulbecco’s phosphate‐buffered saline, #D8537, Sigma‐
Aldrich). HEK293 cells were lyzed with DDM lysis buffer containing 0.2%
F IGURE 1 Pedigree of a family with early onset dementia.
Affected family members are shown in black, a filled upper quadrant
denotes subjective memory complaints. Further pedigree symbols
are: circle, female; square, male; strikethrough, deceased; and
rhomboid, additional siblings with no specified information. The
index patient is marked by an arrow. Below the symbol, information
about the carrier status of the identified TREM2 variant, the APOE‐
ε4 genotype, as well as the age of disease onset for affected
individuals or the age at last examination for unaffected family
members is shown. The status of the second APOE‐ε4 allele in II:2 is
unsure due to low coverage in exome sequencing. One letter amino
acid code was used for depicting TREM2 protein variants. WT,
wildtype
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DDM (n‐Dodecyl β‐D‐maltoside, #D4641, Sigma‐Aldrich), 150 mM NaCl
(#A1149, AppliChem, Germany), 5 mM HEPES (pH 7.4, #A3268,
AppliChem), 1 mM EDTA (pH 8.0, #E6635, Sigma‐Aldrich), 10% glycerol
(#15523, Sigma‐Aldrich), 2 µM leupeptin hemisulfate (#CN33, Roth,
Germany), 1 mM PMSF (in EtOH, #A0999, AppliChem), 20 mM NaF
(#S7920, Sigma‐Aldrich), 20 mM β‐glycerophosphate (#A2253, Appli-
Chem), and two Complete Mini protease inhibitor cocktail tablets
(#04693124001, Roche Applied Science, Germany) in 50 ml dH2O for
30 min at 4°C. Lyzed cells were transferred to 1.5 ml reaction vessel and
centrifuged at 13,000 rpm and 4°C for 15 min. The supernatant
corresponded with the HEK293 cell lysate and were used for expression
analysis.
2.10 | Western blot analysis
Cell lysates were mixed with 6× Laemmli buffer (SDS loading
buffer) containing 100 mM Tris‐HCl (pH 6.8), 4% SDS, 60%
glycerol, 0.2% bromophenol blue, and 10 mM dithiothreitol (DTT)
in dH2O. For preparation of urea gels 6 M urea was added to the
gel buffer before polymerization as described previously (Prager
et al., 2007). Proteins of the cell lysate were separated by SDS‐
PAGE (sodium dodecyl sulfate‐polyacrylamide gel electrophor-
esis) as described previously (Nagler, Palkowitsch, Rading,
Moepps, & Karsak, 2016). Briefly, protein extracts were trans-
ferred to Amersham Hybond enhanced chemiluminescence (ECL)
nitrocellulose membrane (#RPN2032D, GE Healthcare, UK) and
blocked with 5% skimmed milk powder in TBS‐T (150 mM NaCl,
10 mM Tris, and 0.025% Tween® 20 in dH2O). Primary antibodies
in TBS‐T or blocking buffer were incubated over night at 4°C,
washed three times with TBS‐T and incubated with secondary
antibodies for 1 hr at room temperature. For visualization and
detection of proteins the LICOR Odyssey® imaging system and
the Pierce® ECL western blot analysis substrate (#32106,
Thermo Fisher Scientific) were used.
F IGURE 2 The p.(Gly145Trp) variant alters the morphological changes of TREM2‐expressing cells. (a) Schematic drawing of the TREM2 with
depicted functional domains, corresponding tags (Flag/GFP or myc) and the epitope binding region of the anti‐TREM2‐antibody. N‐glycosylation sites are
designated as N20 and N79, immunoglobulin‐like domain as Ig_V‐set domain, transmembrane domain as TM, intrinsically disordered region (IDR) is
highlighted as a meandering line. Protein position glycine 145 with its variation to tryptophan is marked by an arrow (G145(W)). The N‐terminal tag is
located downstream of the signal peptide. (b–d) Representative fluorescent images of COS7 cells coexpressing TREM2WT, TREM2Gly145Trp, or
TREM2Thr66Met with DAP12 upon 2 hr incubation with monoclonal antibody. A continuous line highlights the shape of the cell at the beginning of the
experiment, dotted lines represent the cell shape at the end of the measurements. Changes in cell size were determined by subtraction of both areas.
(e) Quantification of the cell size in different variants. Data are presented as means ± SD (−25.87 ± 21.06% for WT; −8.2 ± 20.09% for TREM2Gly145Trp,
and −4.22 ± 13.19% for TREM2Thr66Met; n = 5 experiments, with 11–16 cells per condition in total. (*p < ,05; **p < .01). One letter amino acid code was
used for depicting TREM2 protein variants. GFP; green fluorescent protein. WT, wildtype
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2.11 | Digestion of membrane fractions by
glycosidases
To investigate glycosylation pattern of TREM2 protein variants
membrane fractions from HEK293 cells transfected with expression
plasmids of WT and p.G145W TREM2 (signal peptide‐Myc‐hTREM2‐
FLAG) were digested with the glycosidases Endo H and PNGase F
(NEB), respectively. Of note, glycosidase digestion was performed in
a reaction end volume of 20 µl and due to the presence of 1% NP‐40
in STEN lysis buffer used for the membrane fraction preparation, the
addition of further NP‐40 was not necessary. Membrane fractions
were mixed with denaturation buffer and incubated at 100°C for 10
min. Afterwards glycosidases and corresponding reaction buffers
were added, followed by incubation at 37°C for 1 hr. For control
denatured membrane fraction with reaction buffers only was
incubated. After glycosidase digestion membrane fractions were
mixed with SDS loading buffer and analyzed by SDS‐PAGE on 12%
SDS separation gels and immunoblotting.
2.12 | Biotinylation of cell surface proteins
For biotinylation of cell surface proteins HEK293 cells were seeded
on poly‐L‐lysine‐coated 6‐well plates (1 × 106 HEK293 cells per
well). About 24 hr after seeding, HEK293 cells were transfected with
Lipofectamine 2000 and Opti‐MEM® according to manufacturer’s
protocol and kept for 24–32 hr at 37°C and 5% CO2. Signal peptide‐
Myc‐hTREM2‐WT‐FLAG or signal peptide‐Myc‐hTREM2‐Gly145Trp‐
FLAG, respectively, were transfected together with hDAP12 plasmid.
About 16 hr prior, biotinylation cells were washed briefly with PBS
and conditioned medium was replaced by DMEM without FCS and
antibiotics. To prevent internalization of cell surface proteins the
following steps were performed on ice and with ice‐cold solutions,
respectively. First, cells were washed three times with ice‐cold PBS.
Then 2 ml of ice‐cold and freshly prepared sulfo‐NHS‐biotin solution
(c = 0.5 mg/ml in PBS) were added and cells were incubated for 30
min on ice under moderate shaking. To block unbound sulfo‐NHS‐
biotin cells were washed for two times with ice‐cold glycine solution
(20 mM in PBS), followed by a third washing step with ice‐cold
glycine solution lasting 15 min on ice under moderate shaking.
Afterwards cells were washed with ice‐cold PBS and lysed by the
addition of 400 µl STEN lysis buffer (150 mM NaCl, 50 mM Tris, 2
mM EDTA, 1% NP‐40, 1% Triton X‐100 in dH2O, and pH 7.4) per well
and incubation on ice for 15 min. Cell debris was removed by
centrifugation at 12,000 g and 4°C for 10 min. To capture
unbiotinylated proteins as a loading control, 20 µl of the samples
were removed and prepared with 5 µl SDS loading buffer and stored
at −20°C until SDS‐PAGE. For biotinylation, 50 µl of washed
streptavidin agarose slurry was added to cell lysates and incubated
over night at 4°C by end‐to‐end rotation. Protein–agarose complexes
were washed four times with STEN washing buffer (150 mM NaCl, 50
mM Tris, 2 mM EDTA, 0.2% NP‐40, in dH2O, and pH 7.6) by
end‐to‐end rotation at 4°C for 10 min. Afterwards protein–agarose
complexes were pelleted by centrifugation at 600 g and 4°C for
3 min. After washing procedure 25 µl SDS loading buffer (100 mM
Tris‐HCl [pH 6.8], 4% SDS, 60% glycerol, 0.2% bromophenol blue, and
10 mM DTT in dH2O) was added and samples were incubated at
70°C for 10 min. Biotinylated protein precipitates and cell lysate
controls were analyzed by SDS‐PAGE on 12% SDS separation gels
and immunoblotting. The images were quantified by Image J software
(Schneider, Rasband, & Eliceiri, 2012).
2.13 | Cell morphology assay
COS‐7 cells coexpressing human TREM2‐GFP and DAP12 were
seeded onto 35 mm µ‐dishes (IBIDI, Germany) and changes in
cell morphology were assessed as previously described (Glebov,
Wunderlich, Karaca, & Walter, 2016). Briefly, 24–36 hr posttransfec-
tion COS‐7 cells were monitored by fluorescence microscopy (ZEISS
Axiovert 200M) for 10 min to determine spontaneous changes of the
cell area. Thereafter, monoclonal anti‐myc antibody (1 µg/ml) was
added to the medium and imaging was continued for additional 2 hr.
Changes in cell surface area were determined by subtracting the area
after 2 hr of stimulation from that before stimulation. Images and
measurements of the cell area were performed using ZEN Blue
edition software (Zeiss, Germany). The specificity of the assay was
confirmed with isotype control mouse monoclonal antibodies (6E10
against β‐amyloid) as previously reported (Glebov et al., 2016). The
TREM2Thr66Met served as a positive control. About 10–16 cells per
condition were imaged.
2.14 | Statistical analysis
All data are presented as mean ± SD. Statistical comparisons among
groups were performed by two‐way analysis of variance (ANOVA)
test. When comparing two groups, we used two‐tailed Student’s
t tests. The p ≤ .05 was considered statistically significant. Data from
assay for cell morphology experiments were analyzed by one‐way
ANOVA with Dunnett ad hoc posttest. GraphPad Prism 7 (GraphPad
software) was used for data analysis.
3 | RESULTS
3.1 | Whole‐exome sequencing (WES) in a family
with dementia revealed a rare coding variant in
TREM2
In our neurology outpatient clinic, a patient consulted with symptoms
compatible with a cognitive disease. This patient (III:1, Figure 1) was
a 57‐years‐old female who initially presented symptoms of progres-
sive cognitive decline at 53 years of age. The first symptoms
comprised forgetfulness of recent conversations and difficulties to
find things in a familial environment (e.g., at home). She was
repetitive in conversations and easily forgot recent facts. One year
after disease diagnosis the family reported language problems with
difficulties of naming ordinary things. Two years after diagnosis, her
activities of daily living declined progressively, requiring supervision
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and becoming soon fully dependent on external help. Her relatives
reported previous medical history of anxiety and a benign breast
tumor. Neurological examination revealed nonfluent global aphasia,
with anomia, semantic and phonemic paraphasia, and difficulties to
understand orders of more than one item as well as imitatory apraxia.
There was left hemineglect with difficulties to fix the gaze (optical
ataxia). Mini‐Mental (MMSE) score was 4/30 and severe cognitive
impairment did not allow further neuropsychological assessment.
There was no limb weakness. Muscular tone was normal and
generalized hyperreflexia was observed. No myoclonus or other
movement disorders were found. She could stand with no help but
did not know were to go by herself without gestural indication. A
brain MRI scan performed 2 years after disease onset in a different
center (pictures not available) was reported to exhibit diffuse cortical
atrophy. She was diagnosed with early‐onset probable AD‐type
dementia (primary progressive aphasia which rapidly evolved
towards posterior cortical atrophy syndrome). Exploring her family
history revealed that her mother (II:2) was also diagnosed with
probable AD dementia with subjective onset of memory impairment
starting at the age of 76 years (Figure 1). At the last visit of the index
patient, her mother was 88 years old and was reported to exhibit
severe dementia according to her family relatives. No more medical
information was available. Moreover, the deceased maternal grand-
mother of the index patient (I:2) was also reported to have had a
dementia disease. In addition, a sister of the index patient, individual
III:3 (Figure 1), reported subjective memory complaints starting at
the age of 40 years, unfortunately we could not follow‐up this
individual in more detail.
The familial clustering of dementia led us to assume the
existence of a genetic susceptibility variant with relatively high
penetrance leading to dementia with a variable age at disease
onset, which can manifest already at the age of around 50 years.
The index patient in this family (III:1) was APOE‐ε4 negative and
targeted sequencing revealed no variations in PSEN1 (presenilin
1), PSEN2 (presenilin 2), or APP (amyloid beta precursor protein).
For this reason, we decided to search for underlying genetic
variant(s) by performing WES (for more details see Material and
Methods) in the DNA samples of both living affected family
members (II:2 and III:1) and one member (II:3) who was
cognitively healthy until the last visit at the age of 71 years,
and, therefore, was operationally classified as healthy. Given the
suspected mode of inheritance, we set up the bioinformatic filters
to search for rare heterozygous variants (MAF < 0.02%) present
in both affected members and not in the unaffected member of
the family. We focussed our search on variants predicting protein
truncation, splicing disturbances, and/or amino acid exchange.
In a first step, we analyzed the exome data for known
monogenic disease genes involved in autosomal dominant forms
of early onset dementia, however, no rare variants were identified
in APP, GRN (granulin precursor), MAPT (microtubule associated
protein tau), PRNP (prion protein), PSEN1, and PSEN2, although the
coding part of these genes were sufficiently covered. Analyzing the
exome data concerning the single nucleotide polymorphisms (SNPs)
rs429358 and rs7412, that is, the two SNPs underlying the APOE‐ε
polymorphism, showed very low coverage for rs7412, which was
probably due to the high GC content of this region. However, both
III:1 and II:3 showed sufficient coverage for rs429358, which in fact
defines the ε4 allele. Both were proven to be negative for the ε4
allele (i.e., “T/T”). For II:2, there was relatively low coverage for
rs429358, which, however, also suggested the absence of the ε4
allele, although we cannot definitely exclude the presence of one ε4
allele. As to be expected for the subsequent exome‐wide analytical
step in a relatively small number of close relatives, we identified
variants in around 65 different candidate genes. However,
the genes carrying these rare variants had no obvious link to
hereditary neurodegenerative dementias with one single exception,
that is, a rare variant in exon 3 of TREM2 (RefSeq
NM_018965.3:c.433G>T/p.[Gly145Trp]). Finally, we did not detect
potentially damaging rare variants fulfilling above mentioned
criteria in ABCA7, ABI3, and SORL1 for which previous reports
identified damaging rare variants in sporadic and familial AD
(Bellenguez et al., 2017; Sims et al., 2017).
We, therefore, focused our research on TREM2
p.(Gly145Trp). This variant predicts a substitution of glycine by
tryptophan in the extracellular domain of TREM2 at amino acid
position 145 and was predicted to be “probably damaging” (score
of 0.988) by Polyphen‐2 (http://genetics.bwh.harvard.edu/pph2/;
assessed on July 17th, 2019) and to “affect protein function”
(score of 0.02) by SIFT (https://sift.bii.a‐star.edu.sg/sift‐bin/SIFT_
seq_submit2.pl; assessed on July 17th, 2019). It was neither
found in 1,269 in‐house controls nor in 1,403 sporadic AD
patients of Spanish or German decent and was present only once
(in an individual of European [non‐Finnish descent] in 251,150
control alleles in the Genome Aggregation Database (gnomAD;
https://gnomad.broadinstitute.org/). It is specifically not present
in 34,570 alleles of individuals of the Latino population making it
rather unlikely that it has a substantial frequency in the Spanish/
Portuguese population. Interestingly, if restricting the gnomAD
analysis to the so called “non‐neuro” population (comprising
207,844 alleles) there is no occurrence of this variant, meaning
that the single individual with the p.Gly145Trp variant in
gnomAD has a neurological phenotype. This variant in TREM2
was also identified in a heterozygous state in the putatively
affected individual III:3 (Figure 1), however, also the as yet
healthy family member III:2 (61 years of age) has this variant in a
heterozygous state. Due to the known meaning of TREM2
variants for different types of familial forms of dementias and
the compatibility of the segregation of the variant with the
clinical findings in the family (allowing for incomplete pene-
trance), we considered the p.(Gly145Trp) variant in TREM2 as the
prime candidate for disease susceptibility in this family, which
was, therefore, further analyzed in biochemical and functional
cellular studies. Notwithstanding, we cannot rule out that further
variants in additional genes may also contribute to the increased
disease susceptibility, which, however, was not the focus of
this study.
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3.2 | The p.(Gly145Trp) variant compromises
TREM2 signaling activity
Ligand‐induced activation of TREM2 results in Ca2+‐mediated
rearrangement of the cytoskeleton accompanied by cell morpholo-
gical changes (Glebov et al., 2016; Kiialainen et al., 2007; Peng et al.,
2010). To compare the signaling activity of the novel TREM2Gly145Trp
variant to that of the wildtype protein (TREM2WT), we used N‐ and
C‐terminally tagged TREM2 constructs with c‐Myc epitope and
eGFP, respectively (c‐Myc‐TREM2‐eGFP; Figure 2a). The c‐Myc
epitope tag served the purpose of specifically activate TREM2 by
antibody cross‐linking, whereas the eGFP signal was used to identify
TREM2‐expressing cells (Figure 2b; Glebov et al., 2016; Takahashi,
Rochford, & Neumann, 2005; Wunderlich et al., 2013). Activation of
the TREM2WT by anti‐c‐Myc antibody resulted in a time‐dependent
decrease in cell size (Figure 2b). Interestingly, cells expressing
TREM2Gly145Trp presented significantly weaker responses upon
activation with the anti‐c‐Myc antibody as compared with the
TREM2WT‐expressing cells (Figure 2c). For further comparison,
we tested a well‐known loss‐of‐function mutant of TREM2, the
p.(Thr66Met) variant. As expected, this variant also showed a
significantly weakened cellular response following TREM2 activation
by anti‐c‐Myc antibody (Figure 2d). The response of the
TREM2G145W‐expressing cells resembled that of cells expressing
TREM2Thr66Met suggesting that the p.Gly145Trp variant impairs
signaling activity of TREM2 (Figure 2e).
3.3 | The p.(Gly145Trp) variant introduces
structural changes in TREM2
The TREM2 variants were also expressed in HEK293 cells, and
immunoblot analysis revealed a main band of ~28 kDa for the
TREM2WT (Figure 3a). We noted that TREM2Gly145Trp variant
migrated slightly faster in SDS‐PAGE (with approx. 2 kDa lower
apparent molecular mass) than TREM2WT. The electrophoretic
migration difference was absent in both additionally tested AD‐
associated TREM2 variants p.(Arg47His) and p.(Thr66Met; Figure
3a). This difference in gel mobility of p.(Gly145Trp) vanished upon
addition of 6 M urea to the SDS gels (Figure 3b) suggesting that
higher electrophoretic mobility of TREM2Gly145Trp likely resulted
from conformational changes. This notion was further corroborated
by immunoblotting with anti‐Myc antibody recognizing the c‐Myc
epitope at the N‐termini, and with anti‐FLAG antibody directed
towards a C‐terminally fused FLAG tag of the tested TREM2 variants,
thereby demonstrating that the differential migration was not a
result of altered proteolytic processing (Figure 3a). The immunode-
tection by an anti‐FLAG antibody also revealed a C‐terminal
fragment (CTF) of TREM2 at ~17 kDa for TREM2WT, TREM2Thr66Met,
TREM2Arg47His, and TREM2Gly145Trp variants (Figure 3a,b). Strikingly,
a generic anti‐TREM2 antibody raised against the human TREM2
ectodomain ranging from H19‐S174 showed markedly reduced
recognition of the TREM2Gly145Trp variant compared with TREM2WT
(Figure 3a). This strong difference in intensities was neither observed
with the antibody against the N‐terminal c‐Myc‐tag nor the C‐
terminal FLAG‐tag, further supporting a conformational effect of the
p.(Gly145Trp) variant.
3.4 | p.(Gly145Trp) in TREM2 does not induce
changes in membrane localization and glycosylation
pattern
We next sought to explore whether the p.(Gly145Trp) variant
affects expression and cell surface localization of TREM2
(Figure 4a). Transiently transfected HEK293 cells expressing
TREM2WT or TREM2Gly145Trp were surface labeled with EZ‐linkTM
Sulfo‐NHS‐biotin. Quantification of immunoblot signals using the
anti‐TREM2 antibody revealed a reduced protein signal for
TREM2Gly145Trp compared with TREM2WT in both cell lysate and
biotinylated protein fraction (Figure 4a). However, for both
variants the fraction of the protein at the cell surface was equal
when normalized to the amount of TREM2 protein in the cell
(Figure 4b), suggesting that both, mutant and WT, exhibited similar
cellular trafficking efficiency.
The maturation process of TREM2 includes glycosylation
(Kleinberger et al., 2014; Park et al., 2015; Wunderlich et al.,
2013). We, therefore, tested whether the p.(Gly145Trp) variation
affects TREM2 glycosylation that might also contribute to the
differential migration pattern seen in SDS‐PAGE. Membrane
fractions of TREM2‐expressing cells were treated with the N‐
glycosidases EndoH or PNGase F (Figure 4c). Treatment with EndoH
or PNGase F resulted in faster migration of both TREM2WT and
TREM2Gly145Trp at ~30 kDa instead of ~35 kDa in untreated samples
(ctrl). The sensitivity of the main band at ~35 kDa to EndoH also
indicates that this variant contains immature mannose‐rich glycos-
tructures. Interestingly, the altered gel mobility of TREM2Gly145Trp
was still apparent upon deglycosylation indicating that the altered
migration does not result from differences in the glycosylation
pattern.
3.5 | The p.(Gly145Trp) variant shortens the
intrinsically disordered region in TREM2
Finally, we explored the effect of amino acid exchanges at this
position on TREM2 conformation. Sequence analysis of TREM2 using
the Predictor of Natural Disordered Regions database (PONDR;
www.pondr.com, version from Jan 12, 2007) classified the short
sequence stretch connecting the Ig‐like domain with the transmem-
brane region of TREM2 as an intrinsically disordered region (IDR).
Interestingly, the IDR is predicted to start exactly at position 145 and
to end at position 168 (Figure 5a). However, the predicted IDR in
TREM2Gly145Trp is shortened by nine amino acids and only spans
position 154–168.
Further in silico analysis showed that the length of the TREM2
IDR could be differentially influenced by the nature of the amino acid
at position 145 with pronounced shortening of the IDR by large
hydrophobic amino acid residues, while amino acids with smaller
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residues were predicted to have no or rather subtle effects on the
length of the IDR (Figure 5b). To validate the effects of different
amino acid substitutions on migration characteristics of TREM2 in
SDS‐PAGE, the respective TREM2 variants were expressed in
HEK293 cells, and cell lysates subjected to immunoblot analysis.
Interestingly, substitution of Gly145 by phenylalanine resulted in
faster migration of TREM2 very similar to the p.(Gly145Trp) variant,
suggesting that decreasing the length of the TREM2 IDR is
responsible for the increased migration in SDS‐PAGE. In contrast,
substitution of Gly145 by alanine, predicted to have no effect on the
length of the IDR, did not change migratory behavior of TREM2.
Notably, the TREM2Gly145Pro variant, predicted to slightly enlongate
the IDR, revealed slightly decreased migration, while the TREM2-
Gly145Ile, predicted to slightly shorten the IDR also slightly increased
migration in SDS‐PAGE (Figure 5c). Thus, the glycine residue at
position 145 is critical for the structure of the IDR in the TREM2
ectodomain. Together, the combined results indicate that the
identified rare dementia‐associated TREM2 variant p.(Gly145Trp)
causes a conformational change of the IDR which could alter
signaling characteristics upon activation.
F IGURE 3 p.(Gly145Trp) influences the electrophoretic mobility of TREM2 in SDS‐PAGE but not when denatured in 6 M urea. (a) and (b)
Western blot images of protein lysates obtained from HEK293 cells expressing TREM2WT and TREM2Gly145Trp separated by (a) SDS‐PAGE and
(b) 6 M urea‐SDS‐PAGE and immunostained with different antibodies (given in brackets). TREM2Thr66Met and/or TREM2Arg47His were used as a
control. Representative immunoblots from three comparable and independent experiments are shown. One letter amino acid code was used for
depicting TREM2 protein variants. CTF, C‐terminal fragment; FL, full length; IB, immunoblot; Vec., empty vector control; WT, wildtype
F IGURE 4 TREM2Gly145Trp exhibits a
comparable membrane localization and
glycosylation pattern to TREM2WT.
(a) Representative immunoblots of
biotinylated HEK293 cells transfected with
TREM2WT and TREM2Gly145Trp. (b)
Quantification of biotinylated TREM2 upon
streptavidin pull down from the total
TREM2 level. Data are means ± SD n = 6.
(c) Immunoblot analysis of expression and
glycosylation pattern of TREM2WT and
TREM2Gly145Trp transfected in HEK293
cells using endoglycosidase H (EndoH) or
PNGase F. One representative immunoblot
from three independent experiments is
shown. One letter amino acid code was
used for depicting TREM2 protein variants.
IB, immunoblot; Vec., empty vector
control; WT, wildtype
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4 | DISCUSSION
Here, we describe a rare coding variant of TREM2 which shows a
segregation compatible with an incompletely penetrant probable
AD‐type dementia in a family showing familial clustering of dementia.
The identified p.(Gly145Trp) substitution maps to the ectodomain of
TREM2 and induces structural alterations leading to shortening of
the IDR, which in turn decreases TREM2 signaling activity. In TREM2,
the majority of identified pathogenic variations are located in the
extracellular part of the protein (Yeh et al., 2017). Interestingly, the
TREM2 pathogenic variations involved in FTD‐, FTD‐like, and AD
phenotypes, such as p.(Thr66Met), p.(Tyr38Cys), p.(Arg47His),
p.(Val27Met), and p.(His157Tyr), seem to affect TREM2 function
through different pathogenic effects at the protein level, including
conformational changes in the ligand‐binding domain (e.g.,
p.[Arg47His], p.[Thr66Met], and p.[Tyr38Cys]) and/or alter subcel-
lular trafficking and glycosylation (e.g., p.[Thr66Met] and
p.[Tyr38Cys]) or proteolytic shedding (e.g., p.[His157Tyr]) of TREM2
(Kleinberger et al., 2014; Sirkis et al., 2016). In contrast, the TREM2
p.(Gly145Trp) variant likely induces a conformational change of the
IDR domain that connects the Ig‐like and TM domain of TREM2
which impairs cellular response.
The glycine at position 145 of TREM2 sequence is located at
the beginning of the IDR domain. Indeed, intrinsically disordered
regions regularly show reduced binding of SDS thereby changing
the electrophoretic mobility of the corresponding proteins
(Receveur‐Bréchot, Bourhis, Uversky, Canard, & Longhi, 2006;
Uversky, 2009). The fact that TREM2Gly145Trp and TREM2WT
migrated identically under strong denaturating conditions (i.e., 6 M
urea‐containing gels), further supports a conformational effect of the
p.(Gly145Trp) substitution. Glycine is often found in IDRs (Habchi,
Tompa, Longhi, & Uversky, 2014) and variations changing this amino
acid might lead to a change in length of the IDR. Importantly, we
observed that the length of the predicted disordered region
correlates with the electrophoretic mobility of the mutant protein,
that is, a decrease in IDR length results in higher mobility and vice
versa. In line with these findings, we observed that exchanging the
glycine at position 145 by alanine, does not change the mobility of
TREM2. Conversely, other amino acids like phenylalanine or proline
caused a shorting or enlargement of this IDR in TREM2, respectively,
which is mirrored by a corresponding change in the electrophoretic
mobility. Collectively, these results suggest that p.(Gly145Trp)
induces conformational changes in the IDR that links the Ig‐like
domain and the transmembrane domain, which could contribute to
the impaired signaling capacity of TREM2Gly145Trp.
IDRs are dynamically disordered and can rapidly rearrange to
different conformations creating the possibility to adapt and
regulate cellular responses and signaling (Wright & Dyson, 2015).
Dysfunctions of IDRs are often involved in neurodegenerative
disorders, for example, linked to aggregation of amyloid‐β peptide,
tau‐protein, and alpha‐synuclein, each of which contains IDRs
(Levine, Larini, LaPointe, Feinstein, & Shea, 2015; Uversky, 2009,
2015). So far, a variation within the IDR region p.(His157Tyr) has
been previously identified to increase the shedding of TREM2 by α‐
secretase. This increased shedding leads to a reduction of full‐length
mature TREM2 at the cell surface that is able to bind ligands and
trigger cellular signaling (Schlepckow et al., 2017). In contrast,
biotinylation experiments showed similar expression of both
TREM2WT and TREM2Gly145Trp at the cell surface. Thus, our findings
support an additional pathogenic mechanism by which this amino
acid variation in TREM2 might impair signal transduction, namely, by
shortening and altering the flexibility of the IDR domain. In addition,
IDRs play a central role in binding of ligands, or as “flexible entropic
linkers” to separate functional protein domains (Wright & Dyson,
2015). Ligand binding might also induce conformational changes in
F IGURE 5 The p.(Gly145Trp) variant affects the length of the
disordered region in TREM2. (a) Predictions of disordered regions of
the VL‐XT score (Variously characterized Long disordered regions
and X‐ray characterized Terminal disordered regions) using the
PONDR®. The horizontal line represents the cutoff and values above
the cutoff denote propensity for disorder. The dashed blue line
represents values for TREM2WT and the continuous red line for
TREM2Gly145Trp. The position of the variation (p.[Gly145Trp]) and
different TREM2 domains are designated. (b) In silico predictions for
the length of the IDR (intrinsically disordered region) in other
TREM2 variants containing different amino acid substitutions at
position 145. (c) Representative immunoblots (n = 3) of TREM2
variants with substitution of G145. Variants (TREM2Gly145Trp,
TREM2Gly145Phe, and TREM2Gly145Pro) with distinct mobility in SDS‐
PAGE than the TREM2WT are designated by arrows (slightly
increased migration) and by a star (slightly decreased migration).
One letter amino acid code was used for depicting TREM2 protein
variants. aa, amino acid; SDS‐PAGE, sodium dodecyl sulfate‐
polyacrylamide gel electrophoresis; WT; wildtype
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some IDRs which in turn modulates interactions with other partners
(Wright & Dyson, 2015). In that regard it is noteworthy that the
p.(Gly145Trp) substitution showed strongly decreased binding of a
generic TREM2 antibody, indeed suggesting profound changes in the
conformation of the TREM2 ectodomain, which might also mechan-
istically contribute to its pathogenicity.
The identification of an AD‐associated variant in the IDR of
TREM2 further stresses the importance of future research in the
largely ill‐defined role of IDRs in protein function and the possible
involvement of genetic variants within IDRs for disease pathogenesis.
From a human genetics point of view this seems especially
noteworthy as common bioinformatic prediction tools may under-
estimate the functional consequences of variants within IDRs as
compared to variants in well‐structured and highly conserved protein
domains with known functions.
Possible limitations of our study are related to the rather small
size of the family and the variable onset of disease relatively late in
adulthood. Besides the p.(Gly145Trp) variant, our filtering approach
identified rare variants in more than 60 additional genes present in
both affected family members and not present in the healthy family
member, some of which might also contribute to the phenotype.
Even more, the phenotype in this family might be additionally
modulated by the cumulative effect (burden) of several common
variants (MAF > 0.02%) clustered in the affected family member. It
is also not known whether family member II:3, who does not bear
the TREM2 variant, or the healthy family member III:2, bearing the
variant, will remain healthy or develop symptoms at an older age.
Indeed, these kind of questions are typical for the genetic analysis
of both monogenic and complex forms of disease disorders with
onset in the adulthood, variable expressivity, incomplete pene-
trance, and large variability in disease onset. Nevertheless, the
identified TREM2 variant, which is extremely rare in the general
population, does represent the most probable genetic susceptibility
factor in the exome data set analyzed in this study. This conclusion
is further supported by the profound alteration of protein structure
and function observed in TREM2 carrying p.(Gly145Trp). Unfortu-
nately, searching for genetic factors underlying the phenotype
variability is nearly impossible with single families. Identification of
these modifying factors has to be part of large international efforts
analyzing the data of hundreds or even thousands of patients from
families as the one presented in this study. From a clinical point of
view, our results also show that next‐generation sequencing‐based
diagnostic testing in familial forms of dementia should include the
complete coding region of TREM2. The existence of heterozygous
TREM2 variants with relatively large effect size furthermore
emphasizes that pharmacological modification of TREM2 function
may represent an attractive avenue for research with possible
therapeutic implications for AD‐type dementia.
In conclusion, our study provide evidence for a variant located in the
IDR within the extracellular domain of TREM2 causing a loss of the
TREM2 activation capability upon stimulation compared with
TREM2WT. This loss of function might mechanistically explain the
clustering of dementia observed in the family. Furthermore, our study
shows the functional relevance of the IDR domain for the ligand‐
induced signaling of TREM2. Further studies with other rare variants
located in this region, if found, could provide additional information on
the exact functional role of the IDR in TREM2.
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